InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,814.69
(
0.60%
)
US TECH 100
19,717.20
(
0.07%
)
Dow Jones
42,830.80
(
0.89%
)
Brent Oil
78.79
(
-0.35%
)
Bitcoin
62,074.07
(
2.99%
)
Post# of 253342
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120557
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 100387

Monday, 06/13/2011 2:20:31 AM

Monday, June 13, 2011 2:20:31 AM

Post# of 253342
FDA approves GSK/VRX’s Potiga (ezogabine) for partial-onset epileptic seizures:

http://finance.yahoo.com/news/Valeant-and-GlaxoSmithKline-prnews-2921421643.html?x=0&.v=1

Potiga received an FDA CRL in Dec 2010 despite the fact that the advisory panel had unanimously backed approval in Aug 2010 (#msg-57275237).

In the EU, the drug was approved for marketing in Mar 2011 under the brand name, Trobalt.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up